Rentosertib × Biological Age
Did rentosertib reverse biological age by 3–4 years after 12 weeks?
The biological-age signal is real.
The biological-age signal is real. Calling it demonstrated age reversal is not. Six proteomic clocks shifted younger, but this exploratory Phase 2a analysis cannot separate ageing effects from treatment of IPF.
“Rentosertib is the first AI drug, now in Phase 3, and showed reversal of biological age in people across six aging clocks, measuring 3–4 years younger after 12 weeks.”
ORIGINAL CLAIM SOURCEX · @DeryaTR_ · 7 SEP 2026VIEW ORIGINAL POSTWhat the evidence says
CITATION
Zhavoronkov et al. (2026) · Nature Biotechnology
DESIGN
Exploratory proteomic-clock analysis · 42 IPF patients
SUPPLEMENT
Six proteomic aging clocks applied to Phase 2a serum samples
- Six proteomic clocks produced lower predicted biological-age signals in treated arms.
- Rentosertib has advanced to a Phase 3 IPF trial.
- The aging-clock analysis used Phase 2a data from 42 IPF patients, not Phase 3.
- The 3–4 year figure was a peak around week 4, not a demonstrated sustained 12-week reversal.
- Proteomic clock shifts cannot establish reversal of human biological ageing, particularly when disease-treatment effects cannot be disentangled.
The biological-age signal is real. Calling it demonstrated age reversal is not. Six proteomic clocks shifted younger, but this exploratory Phase 2a analysis cannot separate ageing effects from treatment of IPF.